678161-34-7Relevant articles and documents
Inhibitors of unactivated p38 MAP kinase
Bullington, James,Argentieri, Dennis,Averill, Kristin,Carter, Demetrius,Cavender, Druie,Fahmy, Bohumila,Fan, Xiaodong,Hall, Daniel,Heintzelman, Geoffrey,Jackson, Paul,Leung, Wai-Ping,Li, Xun,Ling, Ping,Olini, Gilbert,Razler, Thomas,Reuman, Michael,Rupert, Kenneth,Russell, Ronald,Siekierka, John,Wadsworth, Scott,Wolff, Russell,Xiang, Bangping,Zhang, Yue-Mei
, p. 6102 - 6106 (2007/10/03)
Inhibition of the p38 map kinase pathway has been shown to be beneficial in the treatment of inflammatory diseases. The first class of potent p38 kinase inhibitors was the pyridinylimidazole compounds from SKB. Since then several pyridinylimidazole-based